Drug intelligence / Profile preview

Tiradentes association

Development stage: Preclinical
Lead developer: EMS
Modality: Small Molecules

Overview

Tiradentes association is a combination drug evaluated for the treatment of acute pain in adolescents and adults. The specific active ingredients in this combination are not detailed in the available sources, but it has been studied for its efficacy and safety profile in clinical trials targeting acute pain management. The mechanism of action would depend on the individual components included in the combination, which are not specified here. The product appears to be under investigation rather than approved for general use.

Brand names: Tiradentes association
Other names: Tiradentes association

Targets

NET (Norepinephrine Transporter)MOR (Mu opioid receptor)COX

Beyond the preview

Go deeper on Tiradentes association.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiradentes association.

Explore the full profile